On this page

Folic Acid

Prescription ANDA TE AP Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Folic Acid
Generic name
Folic Acid
Dosage form
Injection, Solution
Route
Intramuscular
Marketing category
ANDA · ANDA
Labeler
Fresenius Kabi USA, LLC
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Folic Acid 5 mg/mL 1720258 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Injection, Solution
Route of administration
Intramuscular
Presentations
4

Regulatory status

Source: Drugs@FDANDC Directory
Application number
089202
Application type
ANDA · Abbreviated New Drug Application
Approval date
February 18, 1986
Sponsor
FRESENIUS KABI USA
Products on application
1
Submissions recorded
10
Products approved under application 089202.
Product Trade name Form Strength Ingredient Status TE Flags
089202-001 FOLIC ACID INJECTABLE FOLIC ACID Prescription AP RS

Therapeutic equivalence

Source: Orange Book
TE code
AP
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 089202.
Type No. Action Status Date Review
Supplement 20 Labeling Approved August 11, 2006 —
Supplement 15 Labeling Approved March 21, 2006 —
Supplement 10 Manufacturing (CMC) Approved December 5, 2002 —
Supplement 8 Manufacturing (CMC) Approved January 20, 1995 —
Supplement 7 Manufacturing (CMC) Approved July 6, 1990 —
Supplement 6 Manufacturing (CMC) Approved December 8, 1988 —
Supplement 5 Manufacturing (CMC) Approved December 8, 1988 —
Supplement 4 Manufacturing (CMC) Approved December 8, 1988 —
Supplement 3 Manufacturing (CMC) Approved December 8, 1988 —
Original application 1 Approved February 18, 1986 —

Review documents

  • 0 · Original application · April 9, 2007

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260121). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260121 HUMAN PRESCRIPTION DRUG · 20241014

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Folic Acid Injection, USP alone is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid as may be seen in tropical or nontropical sprue, in anemias of nutritional origin, pregnancy, infancy or childhood.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Parenteral Administration : Intramuscular (IM), intravenous (IV) and subcutaneous (SC) routes may be used if the disease is exceptionally severe or if gastrointestinal absorption may be, or is known to be, impaired. Usual Therapeutic Dosage — In adults and children (regardless of age): up to 1 mg daily. Resistant cases may require larger doses. Maintenance Level : When clinical symptoms have subsided and the blood picture has become normal, a maintenance level should be used, i.e., 0.1 mg for infants and up to 0.3 mg for children under four years of age, 0.4 mg for adults and children four or more years of age, and 0.8 mg for pregnant and lactating women, per day, but never less than 0.1 mg per day. Patient should be kept under close supervision and adjustment of the maintenance level made if relapse appears imminent. In the presence of alcoholism, hemolytic anemia, anticonvulsant therapy or chronic infection, the maintenance level may need to be increased. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

WARNINGS: WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B 12 is deficient. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal “Gasping Syndrome” in premature infants.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folic acid. To report SUSPECTED ADVERSE REACTIONS, contact XGen Pharmaceuticals DJB, Inc. at 1-866- 390-4411 or FDA at 1-800-FDA-1088 or www.fda. gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Folic Acid Injection, USP is a sterile, nonpyrogenic solution of sodium folate (prepared by the addition of sodium hydroxide to folic acid) in Water for Injection intended for intramuscular (IM), intravenous (IV) or subcutaneous (SC) use. Folic Acid is a complex organic compound present in liver, yeast and other substances, which may be prepared synthetically. It is a yellow or yellowish orange, odorless crystalline powder. It is very slightly soluble in water, insoluble in alcohol, chloroform, ether; readily dissolves in dilute solutions of alkali hydroxides and carbonates. It is chemically designated as: L-Glutamic acid, N -[4-[[(2-amino-1-4-dihydro-4-oxo-6-pteridinyl) methyl] amino]benzoyl]-, and has the following structural formula. C 19 H 19 N 7 O 6 M.W. 441.40 Each mL contains: Sodium folate (equivalent to 5 mg folic acid); edetate disodium 2 mg; benzyl alcohol 15 mg (added as preservative); Water for Injection q.s. Hydrochloric acid and/or sodium hydroxide for pH adjustment (8.0 to 11.0). folic acid structure

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Folic Acid Injection, USP 50 mg per 10 mL (5 mg per mL) is available as: Product NDC: 39822-1100-1 10 mL Multiple Dose, in a flip-top vial, packaged individually. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. PROTECT FROM LIGHT. Retain vial in carton until contents are used. Manufactured in India. Manufactured by: Anthea Pharma Private Limited Mfg. Lic: TS/SGY/2023-112201 Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814 Revised: August 2025 FOLI-AN-PI-00 1500105 logo Rx Only

Adverse event reports

Source: openFDA FAERS
250,152
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: FOLIC ACID. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63323-184-10 63323-184 Fresenius Kabi USA, LLC 1 VIAL, MULTI-DOSE in 1 CARTON (63323-184-10) / 10 mL in 1 VIAL, MULTI-DOSE September 5, 2000
39822-1100-1 39822-1100 XGen Pharmaceuticals DJB, Inc. 1 VIAL, MULTI-DOSE in 1 CARTON (39822-1100-1) / 10 mL in 1 VIAL, MULTI-DOSE November 17, 2019
63323-184 63323-184 Fresenius Kabi USA, LLC — September 5, 2000
39822-1100 39822-1100 XGen Pharmaceuticals DJB, Inc. — November 17, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 11 sections on this page.